Cell Adhesion Molecule CD166/ALCAM Functions Within the Crypt to Orchestrate Murine Intestinal Stem Cell Homeostasis
Sign Up to like & getrecommendations! Published in 2017 at "Cellular and Molecular Gastroenterology and Hepatology"
DOI: 10.1016/j.jcmgh.2016.12.010
Abstract: Background & Aims Intestinal epithelial homeostasis is maintained by active-cycling and slow-cycling stem cells confined within an instructive crypt-based niche. Exquisite regulating of these stem cell populations along the proliferation-to-differentiation axis maintains a homeostatic balance… read more here.
Keywords: homeostasis; cell adhesion; cd166; stem ... See more keywords
CD166 promotes cancer stem cell-like phenotype via the EGFR/ERK1/2 pathway in the nasopharyngeal carcinoma cell line CNE-2R.
Sign Up to like & getrecommendations! Published in 2020 at "Life sciences"
DOI: 10.1016/j.lfs.2020.118983
Abstract: AIMS The present study aimed to investigate the role and underlying mechanisms of CD166 in cancer stem cell-like (CSCs) phenotype of the radioresistant nasopharyngeal carcinoma cell CNE-2R. MAIN METHODS Established CD166-shRNA- CNE-2R cell line by… read more here.
Keywords: egfr erk1; cne; cd166; nasopharyngeal carcinoma ... See more keywords
Praluzatamab Ravtansine, a CD166-Targeting Antibody–Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-21-3656
Abstract: Abstract Purpose: Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue… read more here.
Keywords: drug conjugate; phase; cd166; every weeks ... See more keywords
Serum CD166: A novel biomarker for predicting nasopharyngeal carcinoma response to radiotherapy.
Sign Up to like & getrecommendations! Published in 2017 at "Oncotarget"
DOI: 10.18632/oncotarget.16399
Abstract: The present study aimed to identify whether CD166 can be used as a biomarker for predicting the response of nasopharyngeal carcinoma (NPC) to radiotherapy. The serum concentration of CD166 in patients with NPC were detected… read more here.
Keywords: cne2r cd166; response; cd166 cells; cd166 ... See more keywords
The tumor targeting performance of anti-CD166 Probody drug conjugate CX-2009 and its parental derivatives as monitored by 89Zr-immuno-PET in xenograft bearing mice
Sign Up to like & getrecommendations! Published in 2020 at "Theranostics"
DOI: 10.7150/thno.44334
Abstract: Probody® therapeutics are recombinant masked monoclonal antibody (mAb) prodrugs that become activated by proteases present in the tumor microenvironment. This makes them attractive for use as Probody drug conjugates (PDCs). CX-2009 is a novel PDC… read more here.
Keywords: probody; drug; tumor targeting; 89zr immuno ... See more keywords